SGEN News and Press, Seagen Inc. From 12/12/23

Seagen Inc. (NASDAQ: SGEN) is one of today's top gainers. The company's shares have moved -0.24% on the day to $214.09. Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS,...

2023-12-12 07:18:30 ET More on Pfizer, Seagen, etc. Johnson & Johnson Vs. Pfizer: Better Pharma Stock? Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024 Pfizer: Slimming Down After COVID Franchise And Obesity Pipeline Setbacks Pfizer's b...

2023-12-11 11:40:56 ET More on Seattle Genetics, Takeda Pharmaceutical, etc. Takeda Pharmaceutical Company Limited (TAK) Q2 2023 Earnings Call Transcript Seagen's Acquisition: EU Approval And Potential Upside Takeda: Why I'm Staying Bearish On This Generic Drug Divid...

– 88% of patients with advanced stage classical Hodgkin Lymphoma in trial remained progression free at 24 months – – Investigational regimen that eliminates two commonly used chemotherapy agents, vinblastine and bleomycin, continues to show consistent safety and toler...

2023-12-08 09:00:00 ET Summary Growth by acquisition can accelerate a company's growth, allowing it to quickly gain market share, customers, and new technology. Acquiring companies in different sectors can bring diversification, synergy, and efficiencies to a business. However...

2023-12-06 11:15:12 ET More on SPDR S&P 500 ETF Trust: Only Thing That Matters Is Price; Nasdaq Has Further To Go - Cestrian Capital Research The December Fed Meeting: What To Expect And How To Trade It 2024 Analyst Outlook: Leo Nelissen On Staying Defensive In A...

2023-12-06 09:17:21 ET More on Seattle Genetics Seagen's Acquisition: EU Approval And Potential Upside Seagen gains amid options trades, optimism for FTC approval for Pfizer deal FDA to decide on approving Keytruda/Padcev combo therapy by May 9 Seeking Alpha&...

-- Results of Phase 3 HER2CLIMB-02 trial featured in an oral presentation and official press program at the 2023 San Antonio Breast Cancer Symposium -- Seagen Inc. (Nasdaq: SGEN) today announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA ® (tucatinib) in co...

2023-12-05 16:48:42 ET More on Seattle Genetics Seagen's Acquisition: EU Approval And Potential Upside FDA to decide on approving Keytruda/Padcev combo therapy by May 9 Pfizer CFO reiterates Seagen closing expected later this year, early next year Seeking Alp...

2023-12-04 21:29:35 ET Summary Baker Brothers' 13F portfolio value increased marginally from $17.28B to $17.35B. The largest five stakes in the portfolio are Seagen, BeiGene, Incyte, ACADIA Pharma, and BioMarin Pharma, making up approximately 86% of the portfolio. Stake increa...